Physician profile
Thomas Gregory Comstock
NPI 1497782346
$2,698.01
in general payments reported to CMS, 2019-2025
22 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $644 · 2022: $546 · 2023: $667 · 2024: $412 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,508.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $887.53 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $271.44 | 2021-2024 | Verquvo, Vaxelis, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.59 | 2021-2025 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $197.50 | 2021-2025 | |
| Boston Scientific Corporation | $135.26 | 2023 | Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $115.84 | 2024-2025 | Farxiga |
| Novo Nordisk INC | $115.38 | 2021 | |
| Glaxosmithkline, LLC. | $87.67 | 2021-2023 | Trelegy Ellipta |
| Pfizer INC. | $81.44 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.53 | 2024-2025 | Trintellix |
| Amarin Pharma, INC. | $67.48 | 2021 | |
| Abbvie INC. | $66.47 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.93 | 2022-2023 | |
| Exact Sciences Corporation | $63.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Edwards Lifesciences Corporation | $53.48 | 2023 | Sapien 3 Ultra Resilia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $47.32 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $30.12 | 2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.63 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.51 | 2025 | Caplyta |
| Amgen INC. | $15.96 | 2024 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $13.88 | 2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $13.48 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Comstock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.